Amarin (NASDAQ:AMRN) Surprises on Revenue, but EPS Miss and Restructuring Costs Cloud the Picture
Amarin Corporation plc (NASDAQ:AMRN) reported its first-quarter financial results for 2026 after the bell on Tuesday, delivering a mixed bag that beat analyst expectations on the top line but fell short on earnings per share. The market’s initial reaction has been cautiously positive, with shares trading up roughly 0.3% in pre-market action, suggesting investors are weighing the revenue beat and positive cash flow against ongoing restructuring costs and a wider-than-expected net loss.
EPS and Revenue Versus Estimates
The headline numbers offered a split verdict when held up against consensus forecasts compiled by analysts.
- Revenue: The company reported total net revenue of $45.1 million for Q1 2026, slightly ahead of the analyst estimate of $44.6 million. This represents a 7% increase from the $42.0 million reported in the first quarter of 2025.
- Earnings Per Share (EPS): On a non-GAAP basis, Amarin reported a loss of $0.09 per ADS. This was a significant miss compared to the analyst estimate of $0.09 profit per share. On a GAAP basis, the net loss narrowed to $10.5 million, or $0.03 per share, compared to a loss of $15.7 million, or $0.04 per share, in the year-ago quarter.
- Operating Loss: The operating loss improved to $11.3 million from $16.8 million in Q1 2025, a 32% improvement. However, this figure included $3.3 million in restructuring charges.
The EPS miss is largely attributable to a jump in Cost of Goods Sold (COGS), which surged 62% to $27.4 million. Management attributed this to higher product volumes tied to a new exclusive pharmacy benefit manager (PBM) relationship and initial shipments to Rest-of-World (ROW) partners. This increase in COGS significantly compressed gross margins, which fell from 59.8% in Q1 2025 to just 39.4% in Q1 2026.
Key Takeaways from the Earnings Release
Beyond the headline numbers, the press release revealed several critical strategic and operational developments that are shaping the company’s narrative.
- Improved Cost Structure: Total operating expenses (SG&A, R&D, and Restructuring) fell by 31% to $29.1 million. Excluding the restructuring charge, operating expenses were just $25.8 million—a 38% decline year-over-year. This reflects the success of the June 2025 Global Restructuring plan, which the company says has resulted in approximately $70 million in annualized savings.
- Positive Cash Flow: Amarin generated positive cash flow for the second consecutive quarter. It ended the quarter with $307.8 million in cash and investments, up from $302.6 million at the end of 2025, and remains debt-free. Management reiterated its expectation for positive cash flow for the full year 2026.
- Segment Performance: U.S. VASCEPA sales remained flat at $35.6 million, but management highlighted an 17% increase in branded prescriptions year-over-year, pointing to resilient market share. European revenue of $4.9 million was down 9% versus a year ago, but the company noted this was due to the transition to a fully partnered model with Recordati. Encouragingly, European product revenue grew sequentially from Q4 2025, a sign that the new distribution strategy is gaining traction.
- Strategic Initiatives: The company is actively working with Barclays, its exclusive financial advisor, to explore “additional potential pathways to further enhance shareholder value.”
Outlook vs. Analyst Estimates
Management did not provide formal quantitative guidance for the remainder of 2026, but they did offer a clear qualitative outlook. CEO Aaron Berg stated the company is “positioned well for 2026” and reiterated the expectation for full-year positive cash flow.
For the second quarter, analysts are currently forecasting sales of approximately $44.0 million and an EPS of $0.09. For the full year 2026, the consensus estimate stands at $178.9 million in sales and an EPS of $0.39. While the revenue beat and bullish commentary on European growth are supportive, the EPS miss in Q1 sets a high bar for the remaining quarters to hit those full-year profitability targets.
Market Reaction
The pre-market performance, showing a fractional gain of roughly 1%, indicates a muted but positive reception. Investors appear to be focusing on the positive aspects of the report: the expanding international business, the successful cost-cutting, and the strong balance sheet. The market may be looking past the one-time restructuring charges and the temporary margin compression caused by inventory build, betting that the leaner cost structure and growing partner revenue will drive profitability in the back half of the year.
Conclusion
Amarin’s Q1 results tell the story of a company in transition. The old model, reliant on a high-cost U.S. sales force, is being replaced by a leaner organization with a growing international partnership base. While the earnings miss is disappointing, the fundamentals—rising revenue, falling operating costs, and a cash-rich balance sheet—are improving. The market’s guarded optimism suggests that investors are willing to give management time to execute on this new global strategy, but the pressure will be on to show tangible bottom-line improvement in the coming quarters.
Track the Fundamentals
For a deeper look into Amarin’s historical earnings performance and to track future projections against these estimates, you can view all the detailed reports and analyst ratings here:
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Always conduct your own research and consult with a qualified financial professional before making any investment decisions.